[go: up one dir, main page]

WO2003042367A3 - Antibodies that immunospecifically bind to trail receptors - Google Patents

Antibodies that immunospecifically bind to trail receptors Download PDF

Info

Publication number
WO2003042367A3
WO2003042367A3 PCT/US2002/036431 US0236431W WO03042367A3 WO 2003042367 A3 WO2003042367 A3 WO 2003042367A3 US 0236431 W US0236431 W US 0236431W WO 03042367 A3 WO03042367 A3 WO 03042367A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
immunospecifically bind
relates
trail receptors
trail
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/036431
Other languages
French (fr)
Other versions
WO2003042367A2 (en
Inventor
Theodora Salcedo
Victor Roschke
Steven M Ruben
Craig A Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to AU2002352676A priority Critical patent/AU2002352676A1/en
Publication of WO2003042367A2 publication Critical patent/WO2003042367A2/en
Publication of WO2003042367A3 publication Critical patent/WO2003042367A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptors. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TRAIL receptor antibodies, vectors and host cells containing these nuleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor.
PCT/US2002/036431 2001-11-14 2002-11-13 Antibodies that immunospecifically bind to trail receptors Ceased WO2003042367A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002352676A AU2002352676A1 (en) 2001-11-14 2002-11-13 Antibodies that immunospecifically bind to trail receptors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33130901P 2001-11-14 2001-11-14
US60/331,309 2001-11-14
US37797302P 2002-05-07 2002-05-07
US60/377,973 2002-05-07
US40337602P 2002-08-15 2002-08-15
US60/403,376 2002-08-15

Publications (2)

Publication Number Publication Date
WO2003042367A2 WO2003042367A2 (en) 2003-05-22
WO2003042367A3 true WO2003042367A3 (en) 2004-01-29

Family

ID=27406783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036431 Ceased WO2003042367A2 (en) 2001-11-14 2002-11-13 Antibodies that immunospecifically bind to trail receptors

Country Status (2)

Country Link
AU (1) AU2002352676A1 (en)
WO (1) WO2003042367A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3665316B2 (en) 2001-05-18 2005-06-29 麒麟麦酒株式会社 Anti-TRAIL-R antibody
CA2451680C (en) 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
CA2526284C (en) 2003-06-25 2014-11-18 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
KR101235479B1 (en) 2004-08-06 2013-02-20 제넨테크, 인크. Analysis and Methods Using Biomarkers
EP1778871B1 (en) 2004-08-06 2011-05-04 Genentech, Inc. Assays and methods using biomarkers
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2007022157A2 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to ap02l/trail by testing for 'galnac-t14 expression in cells/tissues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRIFFITH T.S. ET AL.: "Functional analysis of TRAIL receptors using monoclonal antibodies", J. IMMUNOL., vol. 162, 1999, pages 2597 - 2605, XP002944456 *
MARIANI S.M. ET AL.: "Interleukin 1beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells", J. CELL BIOL., vol. 137, no. 1, 7 April 1997 (1997-04-07), pages 221 - 229, XP002045027 *
MUHLENBECK F. ET AL.: "The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation", J. BIOL. CHEM., vol. 275, no. 41, 13 October 2000 (2000-10-13), pages 32208 - 32213, XP001062214 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
AU2002352676A1 (en) 2003-05-26
WO2003042367A2 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
WO2003054216A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2002097033A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2001001748A3 (en) Peptide compounds that bind her2
WO2002094192A3 (en) Antibodies against tumor necrosis factor delta (april)
WO2005016236A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
BR0306973A (en) Anti-igf-ir Antibodies and their applications
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004013287A3 (en) Antibodies against c3a receptor
WO2001059064A3 (en) Nucleic acids, proteins, and antibodies
EP2077282A3 (en) Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2004100898A3 (en) Therapeutic use of anti-cs1 antibodies
BE2012C005I2 (en)
WO2003089575A3 (en) Antibodies that specifically bind to tl5
WO2004003144A3 (en) Antibodies that specifically bind to reg iv
WO2003102136A3 (en) Antibodies that specifically bind to neurokinin b
WO2003042367A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2002079377A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2004016753A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003092597A3 (en) Antibodies that specifically bind to chemokine beta-4
WO2005018536A3 (en) Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
WO2003086301A3 (en) Antibodies that specifically bind to tr2
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003078572A3 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP